N
Neuroplast
One of the most promising therapies, which needs dedicated uniform standards and regulations
About Neuroplast
Neuroplast B.V. is a Dutch medical biotechnology company specializing in neuro regenerative medicine. The company focuses on developing advanced stem cell therapies to address neurodegenerative disorders, both acute and chronic. Neuroplast's core product, Neuro Cells, is classified as an Advanced Therapy Medicinal Product (ATMP) by the European Medicine Agency (EMA) and is produced under stringent Good Manufacturing Practice (GMP) guidelines. The company operates in the biopharmaceutical market, serving patients with unmet medical needs related to neurodegenerative conditions. Neuroplast collaborates closely with academic institutions such as the University Medical Center Maastricht and the universities of Maastricht and Hasselt, as well as the Frauenhofer Institute in Aachen. The business model revolves around the development, production, and clinical application of personalized stem cell therapies. Revenue is generated through the commercialization of these therapies, which are designed to slow down or halt inflammatory and apoptotic processes in neurodegenerative diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Geleen, Netherlands
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 80.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, Longevity, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2021 | $11M | $44M | Netherlands Enterprise Agency (RVO) · Brightlands Venture Partners · LIOF - Limburg Regional Development Agency · Lumana Invest | ↗ |
| EARLY VC✓Equity / VC | Feb 2020 | $4.4M | $18M | Brightlands Venture Partners · LIOF - Limburg Regional Development Agency · Lumana Invest | ↗ |
Growth signals
Latest recorded traffic for Neuroplast is 880 monthly website visits, up 41.9% over the last three months. Neuroplast's team grew 71.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Brightlands Venture Partners
LIOF - Limburg Regional Development Agency
Lumana Invest
Netherlands Enterprise Agency (RVO)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neuroplast on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neuroplast’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.